Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11512080 CRBN ligands and uses thereof

Patent 11512080 was granted and assigned to Kymera Therapeutics on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Kymera Therapeutics

Current Assignee

Kymera Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

November 29, 2022

Patent Application Number

16961362

Date Filed

January 14, 2019

Patent Citations

US Patent 10336744 1AP E3 ligase directed proteolysis targeting chimeric molecules

US Patent 10125114 Methods to induce targeted protein degradation through bifunctional molecules

US Patent 10874743 IRAK degraders and uses thereof

Patent Citations Received

US Patent 12091411 IRAK degraders and uses thereof

0

US Patent 11932635 CRBN ligands and uses thereof

0

US Patent 12077555 STAT degraders and uses thereof

0

Patent Primary Examiner

CPC Code

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11512080 CRBN ligands and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool